Skip to main content

Press releases | December 9, 2019

Fried Frank acted as counsel to BofA Securities as financial advisor to Merck in its acquisition of ArQule, Inc. a transaction with an enterprise value of US$2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Merck is a leading global biopharmaceutical company. The transaction is expected to close early in the first quarter of 2020.

The Fried Frank team was led by corporate partner Philip Richter and included corporate associate Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.